Bladder Cancer Academy 2017: Immunotherapy of Renal Cell Carcinoma – UroToday
|
Bladder Cancer Academy 2017: Immunotherapy of Renal Cell Carcinoma
UroToday The next step is combining therapies together, for instance, the VEGF inhibitors together with immunotherapy. There are selective Tyrosine kinase inhibitors (TKIS) together combined with immune check point inhibitors (ICPI). These include axitinib and … |
